News and Media

“Tchaikapharma is the first Bulgarian organization to support the Stand Up To Cancer initiative. What was your motivation and why now?

SU2C is massively supported by the entertainment industry and leading global media with a very critical and self-critical view on the funding and implementation of scientific programs and research. With one important exception for now – we are not developing drugs to treat cancer, but we have a very advanced concept of the key place of complex generics (‘polypills’) in the mainstream therapeutic palette. As Dr Scott Gottlieb, Director of the US Food and Drug Administration (FDA), has said, ‘they are the future of pharmaceutical care’. So to get to mass and affordable treatment of the already epidemic, even pandemic, growth of cancer, we need an epidemic and even pandemic mobilization of resources – financial, scientific, manufacturing. A number of research breakthroughs are needed that the pharmaceutical industry cannot achieve on its own, let alone quickly – in years, not decades. Tchaikapharma shares SU2C’s approach and believes in its impact factor in all directions from fundraising to program selection and implementation.

You can read the full interview here.

The second scientific conference “Fundamentals of Cardiovascular Pharmacotherapy – Combination Therapy” was held in Sofia between May 12-14, 2023 on the initiative of the Academy-Cardiology Foundation, Logartis Foundation and Arbilis Ltd, in collaboration with the Bulgarian Society of Pharmacy and the National Association of General Practitioners in Bulgaria.

As a leading manufacturer of combination products (polypills) in the cardiovascular field, Tchaikapharma High Quality Medicines naturally took part in the event as a gold partner. Among the topics of this year’s conference were “Combination Therapy of Arterial Hypertension”, “Combination Therapy of Coronary Heart Disease”, “Combination Antithrombosis Therapy”, etc.

Pharmacotherapy is the basis of daily clinical practice of all physicians. Good knowledge of the mechanisms of action of drugs, indications for their administration, drug interactions and their dosing according to specific comorbidities is very important for daily practice.

“We have assured quantities of medicines manufactured at Tchaikapharma High Quality Medicines. Based on current consumption, we maintain a minimum of a 4-month supply. If there is increased demand, we are ready to respond.”

Tchaikapharma’s latest medicinal product to receive marketing authorisation from the Bulgarian Drug Agency is Clopasa (colchicine) 0.5 mg tablets – the first gout treatment in the company’s broad portfolio.

Clopasa belongs to the group of medicines with antipathic action. It is used for the treatment of acute attacks of gout, in the condition of chronic gout, for the prevention of acute attacks when starting treatment with other drugs lowering uric acid in the blood and urine or when treating periodic diseases (Familial Mediterranean Fever).

The medicinal product is available on prescription.
ATC code: M04AC01

The newest medicinal product to receive Marketing Authorization from the Medicines Executive Agency is:

Semefro 50 mg/850 mg film-coated tablets

Semefro 50 mg/1000 mg film-coated tablets

Active ingredients: sitagliptin/metformin hydrochloride

Semefro contains two different medicines called sitagliptin and metformin.

– Sitagliptin belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors)

– metformin belongs to a class of medicines called biguanidines.

They work together to control blood sugar levels in adult patients with a form of diabetes called “type 2 diabetes”. This medication increases the levels of insulin produced after a meal and reduces the amount of sugar produced by the body.

Along with diet and exercise, the drug helps lower blood sugar.

The medication can be used alone or with certain other diabetes medications, (insulin, sulfonylurea, or glitazone).

This is a prescription-only medicinal product.

ATC code: A10BD07